LABSPEC 2017
Waikato Scientific Publications’ LabSpec online lab directory and annual print catalogue provide a complete guide for procurement of scientific and medical equipment and services in New Zealand. The site also provides a range of scientific articles. LabSpec offers a mail-out service to keep industry insiders up to date on developments in the laboratory field. Use the search bar above to look for products, manufacturers or local distributors. Search results can be easily cross-referenced to identify similar products, locate possible sources, and narrow your choices down to a few suppliers or products prior to making contact.
Waikato Scientific Publications’ LabSpec online lab directory and annual print catalogue provide a complete guide for procurement of scientific and medical equipment and services in New Zealand.
The site also provides a range of scientific articles. LabSpec offers a mail-out service to keep industry insiders up to date on developments in the laboratory field.
Use the search bar above to look for products, manufacturers or local distributors. Search results can be easily cross-referenced to identify similar products, locate possible sources, and narrow your choices down to a few suppliers or products prior to making contact.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
In a sociation with The NZ Microbiological Society Inc. VOL. 2 No. 1 JUNE 2012 ISSN 172-7101<br />
[ For company contact details see company profiles pages 6 to 26<br />
[ Want a fresh<br />
perspective on<br />
Lab Science in<br />
New Zealand? ]<br />
Issue 115 | October 2016<br />
THE MAGAZINE FOR LABORATORY PROFESSIONALS<br />
Never miss an issue…receive the latest Lab News and BioScience<br />
straight to your inbox. Send your details to: Barb@wbn.co.nz<br />
Check out our facebook page: facebook.com/NZLaboratorynewsandNZBioScience<br />
NOW INCORPORATING<br />
New research targets<br />
drug-resistant breast cancer<br />
Breast Cancer Cure is proud to<br />
commonly known as Herceptin.<br />
announce the funding of two new “Herceptin markedly improves outcomes<br />
for HER2-positive breast cancer. Unfortunately,<br />
treatment resistance develops in many<br />
research projects as part of<br />
The Breast Cancer Research in New patients, leading to a very aggressive disease<br />
Zealand 2016 initiative, a joint<br />
with poor prognosis,” says Dr Hunter.<br />
partnership between Breast Cancer In 2013 a new drug called trastuzumab<br />
Cure, the Health Research Council emtansine (T-DM1) was approved for treating<br />
HER2-positive, metastatic1 breast cancer<br />
of New Zealand (HRC) and The New<br />
that has stopped responding to Herceptin.<br />
Zealand Breast Cancer Foundation. However, T-DM1 shrinks tumours in only half<br />
of patients and the reasons why the other patients<br />
are resistant to it remains unclear.<br />
he first project led by Dr Francis Hunter<br />
from the University of Auckland , will “We’re going to use a powerful genetic<br />
Tsee New Zealand researchers use cutting-edge<br />
genetic technology to help control predict – the sensitivity and resistance to<br />
tool to identify genes that control – and thus<br />
resistance to the latest drug for treating HER2- T-DM1 in HER2-positive breast cancer. Our<br />
positive breast cancer that has spread to other aim is to reduce the distressing uncertainty<br />
parts of the body (metastatic breast cancer). associated with treating this illness and to enable<br />
patients and their caregivers to make in-<br />
Each year more than 3000 New Zealanders<br />
are diagnosed with breast cancer and 600 formed treatment decisions,” says Dr Hunter.<br />
will die from the condition. One-quarter of Phillipa Green, general manager for Breast<br />
these breast cancers are driven by increased Cancer Cure comments: “We are proud to be<br />
amounts of a gene called HER2, which can be able to announce the funding of another vital<br />
research project, to help us move closer targeted with the drug trastuzumab, more<br />
to<br />
achieving our goal of finding a cure for breast<br />
cancer. The work that Dr Hunter is doing is<br />
ground breaking, and will drastically change<br />
the lives and treatment journey of many people<br />
in New Zealand who suffer from Breast<br />
Cancer.”<br />
“This new project takes us to a total of<br />
nine projects funded via the breast cancer<br />
partnership with the Health Research Council<br />
of New Zealand since 2013.”<br />
HRC chief executive Professor Kath<br />
McPherson says recurrent HER2-positive<br />
breast cancer is a major challenge in New<br />
Zealand, particularly as this type of breast<br />
cancer grows rapidly and is associated with a<br />
high risk of metastasis and relapse, with devastating<br />
impacts for the women concerned<br />
and their family/whānau.<br />
“Developing a diagnostic tool that can<br />
predict how patients will likely respond to<br />
the drug T-DM1 – and advancing our understanding<br />
of why some people are resistant to<br />
it – would help improve the chances of survival<br />
for people with this aggressive type of<br />
breast cancer and allow more targeted and<br />
efficient use of expensive cancer medicines,”<br />
says Professor McPherson.<br />
Cancer researcher Dr Tracy Hale from<br />
Massey University has also received funding<br />
Continued on page 4<br />
Airstream® Class II Type A2<br />
Biological Safety Cabinets, Gen 3 (E-Series)<br />
An effective solution in providing operator, product and<br />
environmental protection within laboratories & industrial<br />
facilities.<br />
• Energy-saving and compact<br />
• Stable, self-compensating airflow<br />
• Low Noise and Ergonomic Design • TÜV NORD Certified to EN 12469<br />
info@bio-strategy.com | T: 0800 34 24 66 | www.bio-strategy.com<br />
LN_1016_FS_ESC_AirstreamPlusE_trsfr.indd 1<br />
6/10/2016 12:32:59 p.m.<br />
New Zealand Laboratory news<br />
For more information go to:<br />
www.labspec.co.nz/Publications.aspx<br />
Barbara Hambling<br />
Advertising Manager<br />
07 838 1333 | info@wsp.net.nz<br />
[ 214 ] www.labspec.co.nz [ <strong>LABSPEC</strong> <strong>2017</strong> ]
Change language